Cervical Dystonia Market Growth, Trends and Value Chain 2020-2027

 Cervical dystonia is a neurological movement disorder associated with involuntary movement of neck. It is also known as spasmodic torticollis. As per study it was estimated that women are more prone to get this disorder.

According to a recent study report published by the Market Research Future analysts, the global cervical dystonia market is currently dynamic and growing at a moderate pace. The growth of the market is mainly due to increase in prevalence of Parkinson’s disease, development of new drugs and therapies by players, and greater involvement of the companies in research and development. Besides that, current unmet needs for the cervical dystonia also presents great opportunities for the market players to enter into this market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1416 

That being said, there are few hurdles in the growth of this market such as high cost involved in the research and development leading to the increased cost of the drug, less awareness about the severity of the condition in developing and under developed regions. These factors hinder the cervical dystonia market growth. Global cervical dystonia market is expected to grow at a CAGR of 5% during forecasted period 2017-2023.

Experts say, exciting times are ahead for the cervical dystonia market, as the market events noted above are due to occur against the backdrop of a steadily growing cervical dystonia prevalent population. With the clinical unmet need for better diagnostic tools and treatment options for the affected population, cervical dystonia remains an attractive neurological disorder for drug developers.

Global Cervical Dystonia Market - Competitive Analysis

The global market consist of players such as ALLERGAN (Ireland), Solstice Neurosciences LLC (U.S.), Ipsen Biopharmaceuticals Inc. (France), Merz Inc (U.S.), US WorldMeds, LLC (U.S.) Addex Therapeutics (Switzerland), Revance Therapeutics, Inc.(U.S.), and many other. These are some of the prominent players at the forefront of competition in the global cervical dystonia market and are profiled in MRFR Analysis report.

The global cervical dystonia market is a dynamic market with number of drugs and therapies available in the market. There are few number of companies involved in the development of the drugs which are now widely used all across the world for the treatment of cervical dystonia. There are great developments happening in cervical dystonia therapeutics space.

Due to increasing prevalence of cervical dystonia globally many of the companies are in the race to introduce better oral treatment for cervical dystonia. Companies are using a trend of strategic alliance and acquisition to gain the market and minimize the competition in the market.

Revance Therapeutics Inc. in 2016 initiated a Phase II study of RT002 for the treatment of cervical dystonia. The Company completed its Phase II program recently. In November 2017, the company announce the completion of its Phase II program with a positive results. The company now plans to carry out Phase 3 Program for RT002 Injectable to treat Cervical Dystonia.

ALLERGAN has introduced BOTOX (onabotulinumtoxinA) for treatment of cervical dystonia. It is prescribed to 16 and older people suffering from cervical dystonia. It is an intramuscular drug.

Solstice Neurosciences LLC has introduced MYOBLOC (rimabotulinumtoxinB), which was the first FDA-approved treatment for cervical dystonia. It is used for the treatment of cervical dystonia in adults to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

Ipsen Biopharmaceuticals Inc. a French company introduced Dysport (abobotulinumtoxinA) for the treatment of adults with cervical dystonia.

Global Cervical Dystonia Market - Regional Analysis

Americas has the largest cervical dystonia market. Increasing people suffering from cervical dystonia in America has help to increase the market in this region. Beside this, rise in neurotoxin market, increase in treatments for muscle movement disorders and increasing aging population in this region has fuelled the growth of this market in American region. Due to a huge aging population in Canada the market is developing at a significant rate in this region. As per study, women are more prone to cervical dystonia than men.

Europe has the second largest market which majorly contributed by UK, Germany and France. Well-developed healthcare sector, improved infrastructure and increase in healthcare spending have increased the market in this region.

Asia Pacific is expected to be the fastest growing region for the cervical dystonia market. Asia Pacific is the developing region and a huge population base in this region is the major factor for the growth of the market. Beside this continuous development in healthcare sector and increasing aging population in Asia Pacific has provided fuel for the growth of the market. India and China are the major market of the cervical dystonia.  Due to less development in medical and healthcare sector, Middle East and Africa region contributes least in the cervical dystonia market at present.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cervical-dystonia-market-1416 

Surgical Instrument Tracking Systems Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 Global Surgical Instrument Tracking System Market is expected to register a CAGR of 15.1% during the forecast period and expected to hit USD 567.44 Million by 2027.

Surgery requires a precise assortment of instruments, as many as 200 for a lengthy, complicated procedure, constantly organized before, during, and after the operation. The infection can be incurred by patients if the surgical instrument is left inside patients. According to a research paper published in the National Center for Biotechnology Information (NCBI), the ratio of patients with surgical instruments left inside in 2017 was between 0.3 to 1.0 per 1,000 abdominal operations. There are 1,500 instances of retained surgical instruments based on 28 million estimated operations performed in the US on an annual basis. The requirement of better inventory and asset management practices and growth of the surgical instruments market are expected to drive the surgical instrument tracking system market growth during the forecast period of 2020 to 2027. The Obesity Surgery Society of India reported that there had been a 100-fold increase in weight-loss surgeries in India in just 15 years. The number of weight-loss surgeries in India has shot from 200 in 2004 to a whopping 20,000 in 2019. Almost 1.3 million pregnant women had their babies by C-section in the United States in 2017, according to data released earlier this year [pdf] by the Centers for Disease Control and Prevention (CDC).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1391 

Other factors that drive market growth is to meet the unique device identification rules of the Food and Drugs Administration (FDA). Certain devices intended for multiple use and reprocessed before each use will require direct marking of the UDI on the device itself (many of these are surgical instruments). Product marking will be essential for latex gloves, catheters, basic surgical sponges, and other commodity supplies. However, the advancement and rising adoption of robotic surgery might reduce the number of surgical instruments used per surgery. Thus, government regulations and the implantation of new norms for instrument tracking are anticipated to increase the rate of market growth.

Segment Analysis

Global Surgical Instrument Tracking System Market has been segmented based on Components, Technology, and End-Use.

The market, based on components, has been segregated into hardware, software, services, and others. The hardware segment is further sub-segmented into tags, readers, and others.

Based on technology, the surgical instrument tracking system market has been divided into barcode tracking and radio frequency identification.

On the basis of end-use, the surgical instrument tracking system market is bifurcated into hospitals and others.

Regional Analysis

Global Surgical Instrument Tracking System Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to hold the largest share of the global surgical instrument tracking system market during the assessment period owing to the regulatory reforms. Some of the renowned companies operating in the region include Fortive Corporation, Becton, Dickinson and Company, and Key Surgical. A large number of surgical procedures are expected to fuel the surgical instrument tracking system market in the region. The market in Europe is expected to propel during the forecast period, owing to factors such as rising government initiatives and the increasing number of vendors involved in the barcoding of instruments. In the UK, the Department of Health and MHRA guidance states that hospitals need to track instruments to at least tray level. Using GS1 barcodes means all instruments are traceable from production to the point of care. For patient safety, this is vital as it helps save track instruments. Lost instruments can cost a 500-bed hospital over £100,000 (USD 13,317) per year. Major companies are focusing on adopting international norms in Asian countries to increase patient safety and efficiency of inventory management. For example, Elite Medical, an Australian supplier of surgical tools with a presence of over 30 years in the region, provides instruments and tray tags, which includes smart tags, plastic tray tags, metal tray tags, RFID mesh tray tags, and others for tracking. The surgical instrument tracking system market in the Middle East & Africa is expected to witness a modest market growth rate from 2020 to 2027.

Key Players

MRFR recognizes the following companies as the Key Players in the global surgical instrument tracking system market— Getinge AB (Sweden), Becton, Dickinson and Company (US), Fortive Corporation (US), B. Braun Melsungen AG (Germany), Steris PLC (Ireland), Stanley Black & Decker, Inc. (US), Material Management Microsystems (US), Key Surgical (US), Haldor Advanced Technologies (US), TGX Medical Systems (US) and Others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/surgical-instrument-tracking-system-market-1391 

Ventilator-Associated Pneumonia Market to Witness Widespread Expansion During 2020-2027

 Patients in critical care require aid for respiration. Many of them suffer from disease like heart disease which require continuous monitoring by healthcare staff in intensive care unit. Ventilator- associated pneumonia is prevalent among patients admitted to ICUs. It is a significant cause of morbidity and mortality in ICU. This disease results from contaminated pathogen secretions in the lungs. Prolonged use of ventilators in ICU favour the growth of this market. Increase in hospital acquired infection is also another factor contributing for the growth of this market. Prevention of ventilator-associated pneumonia is important to protect the health of patients suffering from life threating diseases.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1377 

Global Ventilator-associated Pneumonia (VAP) Market - Competitive Analysis

June, 2016 - AstraZeneca had announced that the European Commission (EC) has granted marketing authorisation for Zavicefta, which a combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation. AstraZeneca is a global, innovation-driven biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas which are respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology and infection and neuroscience. Company operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. As per company reports, hospital-acquired pneumonia (HAP) denotes the development of lung infections after a patient has been hospitalised for a minimum of 48 hours. However, after 48 hours, the infection develops during the use of incubation and mechanical ventilation, the condition is then called ventilator associated pneumonia (VAP). VAP is generally a severe illness, with patients requiring treatment in the intensive care unit (ICU). The approval includes intravenous use of Zavicefta for the treatment of patients suffering from intra-abdominal infections (cIAI); Complicated urinary tract infections (cUTI), including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); and, the treatment of aerobic Gram-negative infections in adult patients who have limited treatment options. Zavicefta has been developed in response to the urgent need for new antibiotics to treat serious infections that are becoming increasingly resistant, such as multi-drug resistant P. aeruginosa, carbapenem-resistant Gram-negative pathogens, and ESBL-producing Enterobacteriaceae.

Jan, 2016 - Cepheid announced diagnostic collaboration with medimmune and combacte to facilitate clinical trials of new monoclonal antibodies to prevent serious infectious diseases. This Collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, and COMBACTE, a European public/private partnership set up to promote the development of new drugs in the anti-infectives field, to develop a series of rapid diagnostic tests to identify Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in respiratory secretions of mechanically ventilated patients. These tests will be used to help identify patients for MedImmune's MEDI4893 and MEDI3902 clinical programs, which are being conducted within the COMBACTE consortium to explore the use of biologics in preventing ventilator associated pneumonia (VAP) infections in intensive-care-unit (ICU) patients.

Philips Healthcare is one of the major market player in ventilation devices with its products named Respironic NM3, Respironic V680 and Respironic Trilogy 202.

Medtronic plc. is another major market player in this market with product like Puritan Bennet 980, Newport HT70 and Newport e360.

ResMed manufactures ventilation devices named Astral 150 and Astral 100.

Global Ventilator-associated pneumonia (VAP) Market   - Regional Analysis

Globally, Ventilator-associated pneumonia (VAP) market consists of four regions Americas, Europe, Asia Pacific and Middle East & Africa. America is the largest market for Ventilator-associated pneumonia (VAP) whose growth is contributed to increase in prevalence of smoking leading to lung diseases, large number of patients suffering from chronic heart diseases and demand of mechanical ventilators. The market is growing continuously in Europe due to extensive demand of medical devices in hospitals, and increasing healthcare expenditure. Asia Pacific is expected to be the fastest growing market owing to increase in environmental pollution, high incidence of asthma & chronic obstructive pulmonary disease and large patient pool. Moreover, Awareness regarding prevention of hospital acquired infection, pneumonia and quality control measures taken by hospitals for control of nosocomial infection favour the growth of this market. Increasing ageing population and incidence of infectious disease too contribute for the growth of this market in Asia Pacific. On the other hand, the Middle East & Africa region are likely to have a limited but steady growth in the market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377 

Surgical Chips Market to Witness Widespread Expansion During 2020-2027

 The global market for surgical chips is anticipated to surge at a remarkable CAGR throughout the forecast period (2017-2027), asserts Market Research Future (MRFR). A surgical chip is a recognizing coordinated circuit gadget encased in silicate glass and embedded in the body of an individual.

Drivers and Restraints

The global surgical chips market is growing at a luxurious pace; primarily owing to the increasing penetration of technology in healthcare sector, and growing awareness about the use of surgical chips for patient tracking, medical records management, and healthcare quality control. MRFR experts report that the global surgical chips market is at a flourishing stage and is predicted to gain further prominence over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1310 

The market is also inundated with market players constantly indulging in research and development activities to gain a competitive edge over other companies. For instance, in August 2018, researchers at Brigham and Women’s Hospital (BWH) developed 3D bioprinted tubular structures that imitate the human body’s vessels. The 3D bioprinting technique allows for better replications of the tissues’ properties and could potentially offer a viable solution for damaged tissue.

Market Segmentation

The global surgical chips market has been segmented based on type, end-user, and application.

The types in the global market are DNA Chips, brain chips, lab chips, protein chips, tissue chip and others. The DNA chips market is gaining significant traction from several factors, such as large-scale initiatives in the related field, increasing demand for personalized medicine, miniaturization of DNA chips, escalating need for early detection of cancer and consequent diagnosis and therapeutics.

By end user, the market is segmented into hospitals, clinics, research facilities and others. With constant research and development activities undertaken by companies, number of research facilities have cropped up to meet with these demands. Thus, continuous innovations and discoveries are possible only with high availability of research facilities.

By application, the market is segmented into cancer diagnosis and treatment, gene expression, SNP genotyping, genomics, clinical diagnostics, and others. Rising cases of cancer patients, changing lifestyle and unhealthy eating habits have led to subsequent surge in the cancer diagnosis and treatment market.

Regional Analysis

The market is regionally split into the regions of the Americas, Europe, Asia Pacific, and Middle East & Africa.

North America is the largest market for surgical chips globally on account of increasing healthcare R&D expenditure and highly enhanced healthcare technology. The need to curtail costs, growth and increased use of shifting commodity prices also work in favor of the regional market.

MRFR reports that Europe is the second-largest market for surgical chips due to high strength of private label brands coupled with increased competition amongst market players. Constant technological innovations and continuous R&D activities enhance the market development as well.

On the other hand, Asia Pacific is presumed to be a growing market for surgical chips market, demonstrating a spectacular growth on account of government funding and support along with improving economy and constant efforts put by market players to achieve success in the market. For instance, in August 2018, IIT Kharagpur set up India's pioneering Bioelectronics Innovation Laboratory to develop futuristic battery-free implantable medical devices in the form of chips. These chips will be used for treatment of brain, nerve, muscle or spinal cord disorders that are untreatable by using standard medical practices.

The Middle East and Africa market is developing slowly but steadily as the region is attracting new players to venture into the regional market, which is expected to intensify the competition in the market in the near future.

Key Players

Bio-Rad Laboratories Inc. (US), Cepheid (US), Abbott Laboratories (US) Agilent Technologies, Inc. (US) Perkinelmer Inc. (US), Fluidigm Corporation (US), Illumina Inc. (US), GE Healthcare (UK), Thermo Fisher Scientific, Inc. (US), Roche Diagnostics (Switzerland) are some of the companies at the forefront of the market.

Industry News

An Israeli researcher by the name of Dr. Ben Meir Maoz of Tel Aviv University’s biomedical engineering department has developed a brain chip which will allow research on the human brain at levels of detail and precision that were not previously possible. Its specialty is its ability to take a complex system such as the brain, then break it down into subunits, and still preserve the links between these subunits.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/surgical-chips-market-1310 

Throat Lozenges Market Trends Analysis Research Report 2020-2027

 The latest report published by Market Research Future (MRFR) reveals that the global throat lozenges market will surpass a valuation of USD 6000 Mn by the year 2023. Throat lozenges have been receiving a positive response from consumers. Being an easily available OTC product, throat lozenges sales remain strong globally. In addition, they can be easily consumed having no unpleasant taste or smell unlike other medicines. Brands are introducing new flavours to offer more options to consumers, which is impacting positively on the market. Over the years, throat lozenges have become more effective in providing relief. Cold and cough is extremely common all over the world, which continues to drive the demand for treatments and medications that are aimed towards it. The aforementioned factors are supporting the growth of throat lozenges market. The market is projected to witness a compound annual growth rate of 4.20% during the assessment period (2018-2023).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1212 

Throat infections are common, and lozenges are usually the first line of defence for such conditions. Throat lozenges brands continue to leverage marketing tools to increase the commercial visibility of their product.  Other factors that are linked with the growth of global throat lozenges market include the development of new ingredients, rapid product penetration in fast-developing countries and low-price of throat lozenges. However, the availability of alternative treatments and therapies somewhat inhibit the market opportunities for throat lozenges.

Global Throat Lozenges Market: Segmental Analysis

MRFR’s report include a descriptive segmental analysis of the market based on type, ingredient, and indication. By type, the market has been segmented into hard-candy lozenges, soft lozenges, and compressed lozenges.  The hard-candy segment is further sub-segmented into chewy or caramel based medicated tablets and centre filled hard-candy lozenges. The hard candy lozenges segment currently accounts for more than one-third share of the market and is expected to remain highly lucrative during the forecast period. In 2017, over USD 2400 Mn worth hard-candy lozenges were sold globally. By ingredient, the market has been segmented into menthol, eucalyptus oil, mint, peppermint oil, honey & ginger, lemon, and others. Among these, the menthol segment accounts for the largest market share. In 2017, the segment reached a market valuation in excess of USD 1700 Mn and projected to expand at a CAGR of 3.45% by 2023. By indication, the market has been segmented into cold and cough, sore throat, throat diseases, and others. The sore throat segment holds the pole position and the trend is likely to continue over 2023. The segment surpassed a market valuation of USD 2400 Mn in 2017.

Global Throat Lozenges Market: Regional Analysis  

The report also includes a regional analysis of the market that covers Europe, North America, Asia Pacific (APAC), South America and the Middle East & Africa (MEA). Currently, North America and South America collectively account for the largest market share. In 2017, the Americas accounted for more that 31% share of the market.  North America in particular is expected to remain an important market for throat lozenges during the review period. Sales of OTC medial products including throat lozenges will continue to grow in the region in the years to come. Meanwhile, Europe has emerged as the single largest market for throat lozenges. Prevalence of common cold is considerably high in various parts of Europe, which acts as favorable element for the region’s throat lozenges market.

Global Throat Lozenges Market: Competitive Landscape

Bausch Health Companies Inc, Procter & Gamble, Prestige Brands Inc, Wrigley Company, Reckitt Benkiser Group plc, Gepach International, Bliss GVS Pharma Ltd, Thornton & Ross, Ricola AG, Ernest Jackson, Mondelēz International group, GlaxoSmithKline, Pfizer Inc., Doestsch Grether AG are some of the leading companies profiled in MRFR’s report.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/throat-lozenges-market-1212 

Soaring Demand Drives Global Digital Genome Market Growth During the Forecast Period, 2020-2027

 The penetration of advanced technology in the healthcare sector has developed various techniques for studying different parameters in this sector. Digital genome is one such emerging technology that avails the complete set of genes in digital format which aid in the detailed understanding of genes and their biological functions. According to the report that has been published by Market research Future (MRFR), the global digital genome market is anticipated to project significant growth in the coming years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1125 

Market Drivers and Restraints:

The high prevalence of various genetic disorders has generated the emergence of advanced techniques to study the issues and find remedies to them. The digital genome technology allows the scientists to convert a large amount of data into more sorted and simpler format which help them in solving the problems. The digital genome technology provides overall genetic make-up of the disease which aids in making critical decisions regarding the treatment procedures. The high demand for simplified genetic information in order to shorten the time required for understanding the diseases and providing relevant treatments is majorly driving the growth of the global digital genome market.

The rapidly increasing geriatric population, current developments in the biotech sector, increasing prevalence of Alzheimer's disease and increasing research in the field of genomics are some of the major factors that are fueling the growth of the global digital genome market. However, the high cost of digital genome technology, lack of knowledge regarding digital genome, security issues and inaccuracy of the results are likely to create hindrance in the expansion of the global digital genome market.

Market Segmentation:

The global digital genome market has been segmented on the basis of product, application and end-users. Based on product, the digital gnome market is segmented into sequencing services, sequencing instruments, sequencing consumables, bioinformatics and sample preparation kits and reagents.

Based on application, the global digital genome market is segmented into diagnostics, agriculture & animal research, personalized medicine, drug discovery and treatment analysis. Based on end-users, the digital genome market is segmented into research centers and government institutes, academic institutions, pharmaceutical & biotechnology industries, hospitals, and diagnostic centers.

Regional Analysis:

Geographically, the global digital genome market is segmented into four major regions such as Americas, Asia Pacific, Europe and the Middle East and Africa. The global digital genome market is currently dominated by the Americas, owing to the high prevalence of chronic diseases such as cancer and diabetes and increasing research expenditure for development of proper treatments in this region

The skyrocketing demand for personalized medication and targeted therapy in the Europe region is fueling the growth of the digital genome market in this region. Whereas, the Asia Pacific region is anticipated to witness significant growth in the global digital genome market owing to the rapid development in the field of biotechnology and rising healthcare spending in this region.

The Middle East and Africa region accounts for the least share in the global digital genome market owing to the poor primary healthcare services and low penetration of advanced technology in the healthcare sector in various underdeveloped areas of this region.

Competitive Analysis:

The players in the global digital genome market are aiming towards expanding their businesses in the global market by increasing the research and development expenditure for development of upgrades in the field of digital genomes. The strategic mergers and acquisitions are aiding the players in gaining a competitive edge in the global digital genome market.

In June 2018, Digital DNAtix Ltd., a genetic blockchain company, has announced the pilot of a blockchain-based ecosystem and infrastructure for anonymous genetic testing, services and research with the help of digital genomes.

The major players that are highlighted in the report on the global digital genome market by MRFR are Umbel, BiogeniQ, GenomeMe, NanoString, Illumina, Inc. and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/digital-genome-market-1125 

Hepatitis B Treatment Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Overview:

The global hepatitis B treatment market is expected to grow at an approximate CAGR of 5.3% during the forecast period, 2018–2024.
Hepatitis B is a viral infection caused by a hepatitis B virus. This infection lasts for a longer period and can cause many other complications, such as scarring in the liver, liver cancer or liver failure. The person suffering from hepatitis B faces various symptoms such as fever, fatigue, nausea, and muscle aches. The other symptoms include jaundice, swelling in the legs, poor appetite, drowsiness and many more. The key factors contributing the market growth are growing geriatric population, increasing the prevalence of viral infection and growing sexually transmitted diseases among the population contribute to driving the market growth. The World Hepatitis Alliance (WHA), 2017 reported that 52 million children across the world are living with viral hepatitis. Such a huge population suffering from Hepatitis boosts the market growth.
However, the factor such as the side effects or complication caused due to treatment may hamper the market growth. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7817 

Segmentation

The global hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.
Based on type, the market is segmented into acute and chronic. On the basis of treatment, the global hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery  (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.

Regional Analysis

The Americas dominates the global market for hepatitis B treatment. Factors such as the presence of a large number of healthcare companies, increasing geriatric population and high healthcare expenditure among the population within the Americas drives the market. The National Vaccine Information Center reported 3,370 cases of hepatitis B were reported in the US in 2015.

Following similar trends, Europe stood second in the global hepatitis B treatment market. The increased prevalence of viral diseases and growing healthcare expenditure in this region boost market growth. Also, the presence of developed economies, increasing healthcare facilities, and rising government funding for healthcare boost market growth. Asia Pacific was the fastest growing region for the global hepatitis B treatment market in 2017. This can be attributed due to the increasing incidences of HIV infection and rising demand for the treatment of viral infection among the population boosts market growth. 

On the other hand, the Middle East and Africa holds the least share in the global hepatitis B treatment market. The poor economies within the African region and lack of awareness about the treatment methods hinder the market growth.

Key Players

Some of the key players in the global hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and others.

Browse More Details of the Report @  https://www.marketresearchfuture.com/reports/hepatitis-b-treatment-market-7817